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Abstract: Neuron-glia interactions contribute to pain initiation and sustainment. Intra-ganglionic
(IG) secretion of calcitonin gene-related peptide (CGRP) in the trigeminal ganglion (TG) modulates
pain transmission through neuron-glia signaling, contributing to various orofacial pain conditions.
The present study aimed to investigate the role of satellite glial cells (SGC) in TG in causing
cytokine-related orofacial nociception in response to IG administration of CGRP. For that purpose,
CGRP alone (10 µL of 10−5 M), Minocycline (5 µL containing 10 µg) followed by CGRP with one
hour gap (Min + CGRP) were administered directly inside the TG in independent experiments. Rats
were evaluated for thermal hyperalgesia at 6 and 24 h post-injection using an operant orofacial pain
assessment device (OPAD) at three temperatures (37, 45 and 10 ◦C). Quantitative real-time PCR was
performed to evaluate the mRNA expression of IL-1β, IL-6, TNF-α, IL-1 receptor antagonist (IL-1RA),
sodium channel 1.7 (NaV 1.7, for assessment of neuronal activation) and glial fibrillary acidic protein
(GFAP, a marker of glial activation). The cytokines released in culture media from purified glial
cells were evaluated using antibody cytokine array. IG CGRP caused heat hyperalgesia between
6–24 h (paired-t test, p < 0.05). Between 1 to 6 h the mRNA and protein expressions of GFAP was
increased in parallel with an increase in the mRNA expression of pro-inflammatory cytokines IL-1β
and anti-inflammatory cytokine IL-1RA and NaV1.7 (one-way ANOVA followed by Dunnett’s post
hoc test, p < 0.05). To investigate whether glial inhibition is useful to prevent nociception symptoms,
Minocycline (glial inhibitor) was administered IG 1 h before CGRP injection. Minocycline reversed
CGRP-induced thermal nociception, glial activity, and down-regulated IL-1β and IL-6 cytokines
significantly at 6 h (t-test, p < 0.05). Purified glial cells in culture showed an increase in release of
20 cytokines after stimulation with CGRP. Our findings demonstrate that SGCs in the sensory ganglia
contribute to the occurrence of pain via cytokine expression and that glial inhibition can effectively
control the development of nociception.
Keywords: satellite glial cells; calcitonin gene related peptide; cytokine; trigeminal ganglion;
thermal hyperalgesia
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1. Introduction
Inflammation is a complex biological response, which may be caused by various physiological or
pathological conditions affecting different parts of the body. In the peripheral nervous system (PNS),
inflammatory pain may depend on the phenomena occurring inside the sensory ganglia. Neurons
in sensory ganglia are pseudo-unipolar, as their axons bifurcate and project into the brainstem or
spinal cord and the periphery [1], the non-synaptic transmission occurs by released diffusible chemical
messengers, such as cytokines [2] and neuron soma is surrounded by a sheath of a distinct type of glial
cells called satellite glial cells (SGC). These features, which are unique to the PNS, allow the occurrence
of bidirectional communication through the axon to the periphery and center [1], chemical transmission
due to neuroinflammatory substances [2], and neuron–glia interaction leading to cross-excitation [3].
Studies involving in vivo and in vitro settings have reported that neurotransmitters such as substance
P (SP), calcitonin gene-related peptide (CGRP) or adenosine 5’-triphosphate (ATP)) are released within
the sensory ganglia due to inflammatory and neuropathic pain (NP) conditions [4,5]. SGCs respond to
sensory ganglion injury or damage by proliferating, expressing the glial fibrillary acidic protein (GFAP)
and neuroinflammatory substances and forming gap junctions, thus, sharing the characteristics of glia
in the central nervous system [6,7]. In addition, SGCs were reported to have immune properties, as
they express mitogen-activated protein kinase (MAPK) and cytokines [8]. In animal models, results
have shown that there is an increased activity of the SGCs and an increase in the cytokine level during
a pain condition [9,10]. The release of cytokines from the activated glial cells may be responsible for
the persistence of pain by causing neuronal excitation. In an in vitro study, exogenous application of
IL-1β to neurons of trigeminal ganglion evoked differential responsiveness from neurons. This effect
was shown to be mediated by the modification of voltage-gated sodium channels (NaV) and regulated
by the MAPK thereby contributing to inflammatory hyperalgesia [11,12]. IL-6 modulates neuronal
excitability through NaV1.7, which also involves activation of the MAPK pathway [13]. All these glial
factors may help in the regulation of the neuronal microenvironment and the neuronal transmission
of pain, thus indicating a link between glial activation and neurogenic stimulation [14]. This entire
phenomenon occurs inside the trigeminal ganglion (TG), contributing to neurogenic inflammation and
orofacial pain sensation.
Intra-ganglionic (IG) secretion of CGRP modulates the neuronal transmission of pain
signals [15–18]. CGRP is a potent neuroinflammatory mediator, contributing to the development
of peripheral and central sensitization in orofacial inflammatory, neuropathic pain, migraine
and medication overuse-related headache [15,16,19] and a key mediator of neuroimmune
communication [17]. In TG, CGRP is primarily found in the small-medium-diameter neurons whereas
CGRP receptors are found on large diameter neurons and SGCs [18,20]. Moreover, CGRP can induce
its own expression in the trigeminal neurons via a protein kinase A-mediated pathway [21]. Thus,
the CGRP released within the TG can locally affect SGCs and sensitize the primary afferent neurons,
which in turn can activate positive feed-forward circuitries that can initiate and or sustain a painful
event. Therefore, blocking this loop may have a therapeutic effect [22].
The aim of the present study was to investigate the role of the satellite glial cells in TG on
cytokine-related nociception in response to IG administration of CGRP.
2. Results
2.1. Effect of Intra-Ganglionic Calcitonin Gene-Related Peptide (CGRP)
2.1.1. Intra-Ganglionic CGRP Mediates Orofacial Thermal Hyperalgesia
The reward-licking events/face-contact events ratio (L/F) and stimulus duration/face-contact
events were evaluated after IG drug administration and compared with the baseline. These parameters
depend on the contact made by an animal with the thermode to reach the reward bottle. As
the temperature becomes aversive or less tolerable, the animal withdraws more frequently, thus,
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decreasing the L/F ratio and the stimulus duration/face-contact events (seconds). Across the examined
temperature range, both the L/F ratio and the stimulus duration/face-contact events (seconds) were
significantly reduced at 45 ◦C 6 h post-CGRP injection and only L/F ratio 24 h post-CGRP injection,
compared to baseline. This result indicates that tolerance to heat decreases 6 and 24 h after IG
CGRP administration (Figure 1). Six hours after CGRP administration the L/F ratio and stimulus
duration/face-contact events (seconds) were nearly the same at 37 ◦C. After 24 h, there was an
increase in both the values but this effect could not reach statistical significance. The effect of CGRP
administration on allodynia was evaluated by assessing both behavioral outcomes at 10 ◦C. No
significant behavioral changes were observed after CGRP administration compared to the baseline at
the same temperature after 6 and 24 h.
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Figure 1. Behavioral outcome of intra-ganglionic (IG) calcitonin gene-related peptide (CGRP)
administration. (a) The reward-licking events/face-contact events (L/F) ratio (mean ± standard error
of the mean (SEM)) was significantly reduced at 45 ◦C, both at 6 and 24 h after IG CGRP administration.
(b) The stimulus duration/face-contact (s) (Mean± SEM) was significantly reduced at 45 ◦C, at 6 h after
IG CGRP administration. These results i dicate that CGRP decreases the tolerance to heat between 6
and 24 h. Results are pres ted as percent change from untr a baselin at t e respective temp rature.
*: p < 0.05, **: p < 0.01 with paired-t t st. n = 7 rats were assigned to each group.
2.1.2. Intra-Ganglionic CGRP-Induced Thermal Hyperalgesia Is Accompanied by Satellite Glial Cell
Activation in Trigeminal Ganglion (TG)
Several studies have reported that GFAP, an intermediate filament in the cytoplasm, is a marker of
glial cell activation [23–25]. Althoug in normal resting conditions, SGCs do not express GFAP, they do
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so in response to any kind of injury. In the present experiment, glial activation showed a time-related
change in both mRNA and protein expression after CGRP administration. Between 1 and 6 h, GFAP
mRNA expression was significantly higher in the CGRP-injected group than in the control group,
(Figure 2a). The mRNA expression of GFAP decreased 24 h after CGRP administration, although it did
not reach the basal level. This change in mRNA expression was concomitant with an increase in GFAP
protein expression, occurring 1-6 h after CGRP injection, (Figure 2b,c). Both indicate an increase in
glial activity, occurring concomitantly to thermal hyperalgesia at 45 ◦C, 6 h post-administration.
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Figure 2. IG CGRP induced satellite glial cells (SGCs) activation. (a) The mRNA expression of glial
fibrillary acidic protein (GFAP) in the trigeminal ganglion (TG) was significantly increased at 1 and
6 h after IG CGRP administration. Results are presented as Mean ± SEM of the relative expression.
*: p < 0.05, **: p < 0.01 with one-way analysis of variance (ANOVA) followed by the Dunnett t test. n = 5
rats were assigned to each group. (b) Confocal images of immunofluorescent staining of TG sections
with glutamine synthetase (GS, red), GFAP (green), and 4’,6-Diamidino-2-phenylindole dihydrochloride
(DAPI, blue) at 1, 6 and 24 h after IG CGRP administration and contralateral TGs. Colocalization of
GS and GFAP in the SGCs is denoted by white arrow. Scale bar: 20 µm. (c) IG CGRP administration
increased the GFAP pr tein expressi n on the injected side compared to th contralateral side both at
1 and 6 h. *: p < 0.05, with t-test. n = 3 rats were assigned to each group and data were acquired from
three ndependent sections (i.e., examined in three non-overlapping views).
2.1.3. Intra-Ganglionic CGRP-Induced Thermal Hyperalgesia Is Accompanied by Differential
Regulation of Cytokines in TG
Circulating cytokines are known to be involved in the inflammatory pain phenomenon, and
indirect evidence suggests that the cytokines produced inside the ganglion are also involved in pain
initiation and sustainment [23]. To investigate the CGRP-induced cytokine modulation inside the TG,
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we evaluated the mRNA expression of three pro-inflammatory and one anti-inflammatory cytokine,
IL-1β, IL-6, and TNF-α and IL-1RA, in the TG tissues after IG CGRP administration. The expression
of the pro-inflammatory cytokines IL-1β and IL-6 increased between 1 and 6 h compared to the
control group (Figure 3a). However, statistical significance was reached only in the expression level
of IL-1β 6 h after CGRP injection. This significant increase in IL-1β expression coincided with the
thermal hyperalgesia, occurring 6 h after CGRP injection and glial activation. However, 24 h later the
expression level of IL-1β and IL-6 were nearly similar to the control group. The mRNA expression of
TNF-α, a very potent pro-inflammatory cytokine, did not differ significantly between the treatment
and control groups, from 1 to 24 h (Figure 3a). The mRNA expression of anti-inflammatory cytokine
IL-1RA was upregulated between 1–6 h, reaching statistical significance 6 h after CGRP injection.
This coincided with the peak glial activity. A comparison between ipsilateral and contralateral sides
showed increased expression on the injected side at 1 and 6 h for IL-1β, IL-6, and IL-1RA. However, a
statistically significant result was observed only for IL-6 at 6 h (Figure 3b).
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Figure 3. Differential mRNA expres ion t kines after IG CGRP administration. (a) IG CGRP
increased th expression f IL-1β, IL-6 a -1RA at 1 and 6 h after i istration compared to the
saline-injected group. However, the statistically significant result was observed only for IL-1β and
IL-1RA after 6 h. After 24 h, the expression of IL-1β, IL-6 and IL-1RA decreased. TNF-α expression
was similar in all the groups. #: p < 0.05 with one-way ANOVA followed by the Dunnett t test for
comparison with saline injection. n = 5 rats were assigned to each group. (b) A comparison between
ipsilateral and contralateral side showed increased expression on the injected side at 1 and 6 h for
IL-1β, IL-6 and IL-1RA. However, statistically significant result was observed only for IL-6 at 6 h using
one-way ANOVA, *: p < 0.05, n = 5 in each group.
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2.1.4. CGRP Induces Differential Regulation of Various Cytokines from the Glial Cells
To validate the findings of the differential mRNA expression of cytokines in TG and to confirm
their source as glial cells, an in vitro experiment was performed. Overnight incubation of glial rich
culture with CGRP induced the release of various cytokines, as tested using an antibody cytokine
array (Figure 4). Overnight stimulation (12 h) of glial rich culture with 1 µM CGRP led to a more
than 1.5-fold increase in the protein expression of 20 cytokines, no change in 6 cytokines (between
1–1.5-fold change) and down-regulation of 3 cytokines, as compared to control conditions (glial rich
culture exposed to only serum-free medium) (Table 1). Up-regulated cytokines included IL-1β, IL-6,
and IL-1RA. The expression level of TNF-α remained unchanged after CGRP stimulation.
Table 1. Average fold change in the level of cytokines release in glial rich cell culture after exposure to
CGRP compared to control condition.
Cytokine Average Fold Change (n = 3) SEM
MIG/CXCL9 6.81 2.84
L-SELECTIN/CD62L/LECAM-1 4.64 2.55
IL-3 4.08 1.25
LIX 3.81 2.12
IL-2 3.10 0.64
IL-6 2.78 0.40
IL-17 2.71 0.90
FRACTALKALINE 2.69 1.40
CNTF 2.63 1.23
MIP-1α/CCL-3 2.51 1.10
IL-1α 2.50 0.75
IL-13 2.38 0.69
IP-10/CXCL10 2.30 0.92
IL-4 2.23 1.37
GM-CSF 1.98 1.51
IL-1ra 1.96 0.31
CINC-2α/β 1.90 0.75
IL-1β 1.86 0.35
IL-10 1.75 0.77
VEGF 1.64 0.46
IFN-Υ 1.21 0.36
sICAM-1 1.17 0.15
THYMUS CHEMOKINE/CXCL7 1.15 0.69
CINC-3 1.15 0.40
TIMP-1 1.13 0.10
CINC-1 1.13 0.35
RANTES/CCL5 0.95 0.11
TNF-α 0.93 0.45
MIP-3α/CCL20 0.88 0.10
Cytokines released were evaluated in the supernatant using R&D system’s rat cytokine antibody array. 29 cytokines
were simultaneously checked for the change in release after stimulation with 1 µM CGRP. The level of 20 cytokines
was more than 1.5 fold, which included- IL-1β, IL-6 and IL-1RA, 6 cytokines showed 1–1.5 fold change, and three
were below 1 fold. TNF-α expression was found to be below 1 fold change. The average is taken from three
independent experiments, and in each experiment TG from three animals were dissociated and passaged to obtain
glial rich culture. SEM: Standard error of the mean.
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2.2. Effect of Injecting Minocycline (Min) Intra-Ganglionic 1 Hour before Injecting CGRP
2.2.1. Min Prevented the Pro-Nociceptive Effect of Intra-Ganglionic CGRP
In the present experiment, the effect of Minocycline (Min) IG administration 1 h prior to CGRP
on the sensitivity to neutral, hot and cold temperatures was investigated. Within the first 6 h, Min
administration 1 h before CGRP increased the L/F ratio and stimulus duration/face-contact events
(seconds) for all temperatures (i.e., 37, 45 and 10 ◦C), compared to both baseline and administration of
CGRP alone, (Figure 5). This increase was statistically significant at 45 ◦C around 6 h, however at 24 h
it was not statistically significant There was nearly similar behavior outcome for the group receiving
Min + CGRP at 37 ◦C after 24 h compared to the baseline. After 24 h at 10 ◦C, a decrease in L/F ratio
and stimulus duration/face-contact events (seconds) were reduced after Min injection, but it was not
statistically significant.
2.2.2. Min Prevented the Pro-Nociceptive Effect of Intra-Ganglionic CGRP via Inhibition of
Glial Activation
Effect of Min on the glial inhibition was investigated by intra-ganglionic administration of Min
1 h before CGRP and evaluation of mRNA and protein expression of GFAP. The Min + CGRP injected
group exhibited a significantly decreased GFAP mRNA expression between 1 and 6 h, compared to the
group administered CGRP alone, Figure 6a. This decrease occurred concomitantly with a reduction
in GFAP protein expression Figure 6b,c. After 24 h, both groups presented a nearly similar GFAP
expression, which could not reach the basal level. The decrease in glial activity between 1 and 6 h, as
noted by the decreased GFAP mRNA and protein expression, coincided with increased L/F ratio and
stimulus duration/stimulus-contact events (seconds) at 45 ◦C at 6 h in Min + CGRP injected group,
thus, indicating that glial inhibition contributes to increased tolerance to heat.
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Figure 6. Effect of injecting Min 1 h before CGRP on glial inhibition. (a) mRNA expression of GFAP
in TG was significantly decreased 1 and 6 h after administration in the Min + CGRP group compared
to CGRP alone group. Results are presented as Mean ± SEM of relative expression. *: p < 0.05 with
t-test. n = 5 rats were assigned to each group. (b) Confocal images of immunofluorescent staining
of TG sections with GS (red), GFAP (green), and DAPI (blue) after 1, 6 and 24 h of IG Min + CGRP
administration and contralateral TG. Colocalization of GS and GFAP in the SGCs is denoted by white
arrow. Scale bar: 20 µm. (c) IG Min 1 h before CGRP administration decreased the GFAP protein
expression compared to only CGRP injection at 1 and 6 h. *: p < 0.05 with t test. n = 3 rats were
assigned to each group and data were acquired from three independent sections (i.e., examined in three
non-overlapping views).
2.2.3. Min Induced Glial Inactivation Is Accompanied by Reduced Expression of Cytokines in TG
Between 1 and 6 h, Min reduced the CGRP-in uced xpr ssion of cytokines IL-1β, IL-6, and
IL-1RA, which was statistically significant for IL-1β and IL-6 around 6 h after injection (Figure 7). No
significant difference was observed between the CGRP and Min + CGRP injected groups regarding
the expression of any cytokine after 24 h. There was no difference in the expression of TNF-α in
either group.
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2.3. CGRP-Induced Neuronal Activation Is Prevented by Min
Studies involving in vivo and in vitro setting have shown that glial secreted cytokines cause
neuronal excitation. This neuronal excitability may be due to the modification of NaV channels, out of
which NaV1.7 has been reported to be involved [11–13]. In the present experiment, neuronal excitation
was examined by a change in the expression of NaV1.7 after CGRP nd Min + CGRP administration.
In the sensory ganglion, NaV1.7 is primarily distributed primarily in small-diameter neurons, which
also express the CGRP and TRPV1 receptors—a thermal sensor and its activation is responsible for the
detection of painful thermal stimuli [26,27]. Exogenously administered CGRP significantly increased
the expression of NaV1.7 t 6 h, whereas Min significantly reduced the expression of NaV1.7 at 6 h,
(Figure 8). Thus, in the present study, a temporal concordance was noted between glial activation and
neuronal activation, apart from that glial inhibition resulted in reduced neuronal activity.Int. J. Mol. Sci. 2018, 19, x 11 of 20 
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3. Discussion
The neuron–glia cross talk and the role of satellite glial cells in the maintenance of pain are a
well-known concept in pain research. The evidence provided by the present study supports this
concept, by showing that the IG administration of CGRP in the TG caused heat hyperalgesia, extending
between 6 and 24 h post-administration. During 24 h behavior assessment at 37 ◦C, both L/F ratio
and stimulus duration/face-contact showed an increase in the trend beyond the baseline. It cannot be
confirmed based on the results that this effect was due to analgesia or reduced stress to the animals.
However, this effect did not reach statistical significance. Increased glial activity was observed during
the first 6 h, as evaluated by increased mRNA and protein expression of GFAP, and the increased
mRNA expression of the pro-inflammatory cytokine IL-1β and the anti-inflammatory cytokine IL-1RA
in the TG tissues. In our cell culture experiment, CGRP stimulation resulted in an increased expression
of 20 cytokines, as detected by the antibody cytokine array, including IL-1β, IL-6, and IL-1RA. When
Min, a glial inhibitor drug, was injected one hour before CGRP administration, L/F and stimulus
duration/face-contact increased significantly at 45 ◦C after 6 h compared to the CGRP injected group.
A significant reduction of glial activity was observed between 1 and 6 h in the Min + CGRP injected
group, as detected by the down-regulation of the GFAP expression and a significant fall in mRNA
expression of cytokines IL-1β and IL-6 compared to the only CGRP injected group. However, at 24 h,
cold sensitivity showed a reduction, as measured by the L/F and average contact duration in the
Min + CGRP group, although this effect was not statistically significant. In the present study, no
difference was observed among the CGRP, Min + CGRP and saline groups, regarding TNF-α mRNA
expression. Additionally, the cell culture experiment showed that overnight stimulation with CGRP
did not change the expression of TNF-α compared to the control condition. In the CGRP-injected
group, NaV1.7 was upregulated 6 h post-administration, whereas in the Min + CGRP-injected group it
was down-regulated.
A previous animal study showed that the incubation of isolated SGCs with fractalkine induced
the release of TNF-α, IL-1β, and PGE-2 [23]. Differential cytokine regulation was detected with an
antibody array when the glial rich culture was stimulated with CGRP [8,9,28]. A previous study using
rat TG primary cultures reported that 1 µM CGRP was associated with a modest pro-inflammatory
effect by upregulating the expression of inflammatory genes at the mRNA level, without modifying
the secretion of proinflammatory mediators, including IL-1β [29]. However, CGRP potentiated the
level of glial activation induced by IL-1β, thus, showing that SGCs are activated by CGRP released
from neurons, and CGRP + cytokines can have a synergistic effect on glial activation, thus forming
a positive feedback loop within the TG [29,30]. Another study demonstrated the co-expression of
IL-1β/GFAP immunoreactivity in TG satellite cells and a paracrine mechanism of action of IL-1β,
inducing neuronal hyperexcitability in response to inflammation [2,31]. Stimulation of human TG
suspension of SGC with specific toll-like receptor 1-5 ligand caused IL-6 and TNF-α release in the
supernatant [7].
From the results of the present study, it cannot be determined whether the presence of thermal
hyperalgesia at 24 h was due to a peripheral effect or to central sensitization. It has been reported
previously that injecting CGRP or olcegepant (CGRP receptor antagonist) in the TG does not affect
the activity of spinal trigeminal neurons [32]. However, this effect was examined within 20 min of
each treatment. When released at extravascular sites, CGRP can have an extremely long duration
of action [33]. In migraine patients, intravenous infusion of human α-CGRP requires a considerable
amount of time to provoke migraine-like headaches [22,34]. In addition, our findings indicate that
the presence of thermal hyperalgesia between 6 and 24 h post-treatment may involve an unidentified
intracellular mechanism, an extended receptor activation, the endogenous release of CGRP or the
sensitization of TG afferents and/central site that receive input from TG [21,22,33,34].
Intrathecal administration of Min has been found to inhibit low-threshold mechanical allodynia
by decreasing microglial activation and simultaneously decreasing the mRNA expression of IL-1β,
TNF-α, IL-1 RA and IL-10 in the lumbar and dorsal spinal cord, and the expression of IL-1β and TNF-α
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in the cerebrospinal fluid [35]. Intrathecal co-injection of Min and CCL-2 has been found to block the
CCL-2 induced reduction in the latency of hind-paw withdrawal and thermal hyperalgesia [36]. In a
model of sciatic nerve ligation neuropathic pain, Min induced reversal of hyperalgesia and allodynia
by inhibiting IL-6 production [37]. These findings are consistent with our results.
In our experimental condition, TNF-α mRNA and protein expression were relatively unchanged
in all the groups. In antibody cytokine array analysis studies, CGRP stimulation of glial rich culture
showed different results in the fold change of TNF-α by different researchers: >3-fold increase in
TNF-α [8], 50% of control [9], no significant change [28]. This difference in result may be due to
the difference in animal species, the age of the animal used for the experiment, cell density, the
concentration of CGRP or time of stimulation etc. According to a previous study, CGRP-mediated
immunosuppressive activity is due to suppression of TLR-stimulated dendritic cells TNF-α production
by a mechanism involving rapid up-regulation of the transcriptional repressor inducible cAMP early
repressor [38]. In contrast, in an organ culture study of TG, TNF-α mRNA showed highly significant
upregulation when co-incubated with CGRP, which was counteracted by the addition of CGRP8-37
(CGRP antagonist) [39]. TNF-α induces pro-inflammatory signal cascades accompanied with an
increase in the synthesis and release of CGRP by trigeminal ganglion neurons [40] and in migraineurs,
serum TNF- α and IL-1β are shown to be elevated during the attack [41].
There is evidence indicating that glial-secreted IL-1β upregulates the expression of neuronal
NaV 1.7 in the sensory ganglia, thus, contributing for inflammatory hyper-nociception, whereas glial
inhibitors block the inflammation-induced SGCs activation, thus, alleviating inflammation-induced
hyper-nociception [42]. This is consistent with our results since we observed that NaV1.7 upregulation
was accompanied by glial activation, IL-1β upregulation, and thermal hyperalgesia. Moreover, all
these effects were reversed by the injection of Min 1 h prior to CGRP administration. The results of
this study indicate the occurrence of neuronal activation in response to glial-activated secretion of
pro-inflammatory substances and neuron-glia cross-excitation after IG CGRP injection. In animal
studies with knockout/knockdown of NaV1.7, a reduced response to inflammatory hyperalgesia has
been observed [43,44]. In humans, mutations in SCN9A gene (encoding NaV1.7) are related to pain
disorders [45,46].
CGRP is a neuropeptide that plays diverse actions in different parts of the body and several
studies have investigated previously the effect of exogenous CGRP on behavior. In a study with
healthy volunteers, intravenous infusion of CGRP induced mild headache, whereas stimulation of
V1 trigeminal area with noxious heat caused increased neuronal activity in the brainstem and insula,
decreasing neuronal activity in the caudate nuclei, thalamus and cingulate cortex [47]. Microinjection
of CGRP into different areas of the nervous system resulted in differential behavior responsiveness
ranging from increased to decreased nociception [48–54].
This study has certain limitations. Apart from glial inhibition, Min has a neuroprotective
activity by reducing the expression of metalloproteinases, and anti-inflammatory activity by inhibiting
circulating macrophages [55,56]. This study did not probe into these possibilities. The therapeutic
effect of Min was not tested by administering Min after CGRP-induced inflammation. Peltier rods of
the orofacial pain assessment device (OPAD) were programmed to have a similar bilateral temperature
cycle. Therefore, a conclusion about the differential effect of the drug in causing hyperalgesia to the
ipsilateral and contralateral side cannot be drawn. However, according to one study, unilateral injection
of CGRP in hind paw had a bilateral effect due to local and neurogenic inflammatory mechanism, and
endogenous secretion of CGRP [57].
To the best of the authors’ knowledge, this is the first study showing the effect of exogenous IG
CGRP in TG on orofacial thermal nociception and the interplay of cytokines and neuron–glia interaction.
Taking all the findings together, we can conclude that SGCs are involved in pain modulation by
augmenting and sustaining inflammatory processes in the sensory ganglia and that glial inhibition can
be used to effectively treat neurogenic inflammation-associated pain (Figure 9).
Int. J. Mol. Sci. 2019, 20, 711 13 of 20
Int. J. Mol. Sci. 2018, 19, x 13 of 20 
 
CGRP is a neuropeptide that plays diverse actions in different parts of the body and several 
studies have investigated previously the effect of exogenous CGRP on behavior. In a study with 
healthy volunteers, intravenous infusion of CGRP induced mild headache, whereas stimulation of 
V1 trigeminal area with noxious heat caused increased neuronal activity in the brainstem and insula, 
decreasing neuronal activity in the caudate nuclei, thalamus and cingulate cortex [47]. Microinjection 
of CGRP into different areas of the nervous system resulted in differential behavior responsiveness 
ranging from increased to decreased nociception [48–54]. 
This study has certain limitations. Apart from glial inhibition, Min has a neuroprotective activity 
by reducing the expression of metalloproteinases, and anti-inflammatory activity by inhibiting 
circulating macrophages [55,56]. This study did not probe into these possibilities. The therapeutic 
effect of Min was not tested by administering Min after CGRP-induced inflammation. Peltier rods of 
the orofacial pain assessment device (OPAD) were programmed to have a similar bilateral 
temperature cycle. Therefore, a conclusion about the differential effect of the drug in causing 
hyperalgesia to the ipsilateral and contralateral side cannot be drawn. However, according to one 
study, unilateral injection of CGRP in hind paw had a bilateral effect due to local and neurogenic 
inflammatory mechanism, and endogenous secretion of CGRP [57].  
To the best of the authors’ knowledge, this is the first study showing the effect of exogenous IG 
CGRP in TG on orofacial thermal nociception and the interplay of cytokines and neuron–glia 
interaction. Taking all the findings together, we can conclude that SGCs are involved in pain 
modulation by augmenting and sustaining inflammatory processes in the sensory ganglia and that 
glial inhibition can be used to effectively treat neurogenic inflammation-associated pain (Figure 9). 
 
Figure 9. Schematic representation of the effect of exogenously administered CGRP on neurons and 
SGCs. CGRP receptors are present on the SGCs and neurons [namely, receptor activity-modifying 
protein 1 (RAMP1), and calcitonin receptor-like receptor (CLR)]. Injected CGRP causes its activity by 
engaging these receptors and causing activation of SGCs as demonstrated by an increased expression 
of GFAP. Pro-inflammatory cytokines IL-1β and IL-6 are released from the SGCs in the TG and these 
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initiated these effects are self-sustaining because of the formation of a feedback loop due to the 
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experiment. Injecting Min (a glial inhibitor) reduced the effect of CGRP, leading to an alleviation of 
hyperalgesia. 
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Figure 9. Schematic representation of the effect of exogenously administered CGRP on neurons and
SGCs. CGRP receptors are present on the SGCs and neurons [namely, receptor activity-modifying
protein 1 (RAMP1), and calcitonin receptor-like receptor (CLR)]. Injected CGRP causes its activity by
engaging these receptors and causing activation of SGCs as demonstrated by an increased expression
of GFAP. Pro-inflammatory cytokines IL-1β and IL-6 are released from the SGCs in the TG and these
cytokines cause neuronal activation as shown by upregulation of NaV 1.7. Hypothetically, once initiated
these effects are self-sustaining because of the formation of a feedback loop due to the secretion of
endogenous CGRP and responsible for hyperalgesia as observed at 6 h in the present experiment.
Injecting Min (a glial inhibitor) reduced the effect of CGRP, leading to an alleviation of hyperalgesia.
4. Materials and Methods
4.1. Animals
The Animal Research Committee of the Tokushima University approved all animal care and
experimental procedures (Protocol number- T27-78, date 4 November 2015; T30-75 date 27 September
2018). For in vivo experiments, 4-week old male Sprague Dawley rats were habituated to the animal
housing room for 2 weeks and were used for drug administration and behavioral assessment between
6 and 9 weeks of age, at the body weight of 230–280 g. The rats were housed in groups of 2 or 3 rats per
cage, under a controlled light cycle (lights on at 6:00 and off at 18:00). Food and water were available
ad libitum, except when the animals fasted for behavior testing. All efforts were made to minimize
animal suffering and to reduce the number of animals used. All the experiments were performed
between 9:00 and 16:00.
4.2. Anesthesia
Medetomidine (Nippon Zenyaku Kogyo, Fukushima, Japan) 0.375 mg/kg, midazolam (Sandoz
K.K., Yamagata, Japan) 2.0 mg/kg and butorphanol (Meiji Seika Pharma Co., Ltd., Tokyo, Japan)
2.5 mg/kg were administered intraperitoneally to induce anesthesia according to a previously
published protocol [58]. Rapid recovery from anesthesia was achieved by administration of
atipamezole (0.75 mg/kg), an antagonist of medetomidine (Nippon Zenyaku Kogyo Co., Ltd., Tokyo,
Japan). Prior to euthanasia, the animals were deeply anesthetized using sodium pentobarbital (Kyoritsu
Seiyaku Corporation, Tokyo, Japan) 75 mg/kg, administered intraperitoneally.
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4.3. Intra-Ganglionic Drug Administration
The rat α-CGRP (R&D System, Minnesota, MN, USA) solution and Min (Nichi-Iko, Toyama,
Japan) were prepared in normal saline, aliquoted and stored at −20 ◦C, following the manufacturer’s
instructions. For TG IG drug administration, either CGRP alone (10 µL of 10−5 M) [32], Min (5 µL
containing 10 µg Min) followed by CGRP with one hour gap (Min + CGRP), or normal saline (10 µL)
were injected according to a previously published protocol [59]. Briefly, IG administration was
performed using a 26 gauge, 10 µL Hamilton syringe. The canal was accessed from the infra-orbital
foramen, 1 mm medial to the zygomatic process of the maxilla, and the needle was inserted
approximately 22 mm, at an angle of approximately 10◦ toward the midline and approximately
15◦ downward from the plane formed by the parietal bone [59]. The needle traversed through the
infraorbital canal into the ipsilateral trigeminal ganglion located in the Meckel’s cave. Direct blue 1
(TCI, Tokyo, Japan) was injected to confirm the correct location of the injection in the TG.
4.4. Behavioral Assessment
After IG drug administration, rats were evaluated for thermal hyperalgesia at both 6 and 24 h
post-injection [23]. The evaluation was performed in independent experiments, using an operant
orofacial pain assessment device (OPAD, Stoelting Co., Wood Dale, IL, USA, which was a kind gift
from Dr. John Neubert, University of, Gainesville, FL, USA). All the rats were tested only once after
drug administration. The rats were tested on the OPAD at three temperatures (i.e., 37, 45 and 10 ◦C),
within a 15 min behavioral session. A ramping cycle of 60 s, remaining at a temperature for 60 s,
was used during the entire 15 min session, which allowed for testing at the neutral temperature and
for assessing pain at hot and cold temperatures within a single testing session [60]. The rats were
trained at a neutral temperature (i.e., 37 ◦C) to press their faces against temperature-controlled Peltier
rods to gain access to a food bottle filled with diluted sweetened condensed milk (1:2, milk to water)
(Morinaga, Tokyo, Japan) as a reward until they licked at least 1000 times during a 10-min session. The
rats were shaved 1–2 days prior to testing and fasted 18 h before the baseline recording (on 3 different
days with a gap of at least 2 days between each session) and after IG injections (one time).
4.5. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
TGs were dissected after IG drug administration, at 1, 6 and 24 h post-injection and were
immediately stored in RNA later (Sigma-Aldrich, St. Louis, MO, USA) following the manufacturer’s
instructions. Saline-injected rats were used as a control. A tissue lyser was used to homogenize the
tissues. Total RNA was extracted from the trigeminal ganglion using trizol reagent (Invitrogen,
Carlsbad, CA, USA) and reverse-transcribed to cDNA using a high-capacity cDNA reverse
transcription kit (Applied Biosystems, Foster City, CA, USA) following the manufacturer’s instructions.
Quantitative real-time polymerase chain reaction (qRT-PCR) for seven genes was performed to evaluate
the expression of Tbp (TATA box binding protein), IL-1β, IL-6, TNF-α, IL-1RA, NaV 1.7 and GFAP
mRNA. The following primer sequences were selected from previously published research (F, forward;
R, reverse):
IL-1β F_5′-cacctctcaagcagagcacag-3′, IL-1β R_5′-gggttccatggtgaagtcaac-3′ [61], IL-6
F_5′-tcctaccccaacttccaatgctc-3′, IL-6 R_5′-ttggatggtcttggtccttagcc-3′ [61], TNF-α F_5′-aaatgggctccctc
tcatcagttc-3′, TNF-α R_5′-tctgcttggtggtttgctacgac-3′ [61], NaV1.7 F_5′- tcgtac cccatagaccccg-3′,
NaV1.7 R_5′-ctgattagtcgtgccgctg-3′ [62], IL-1RA F_5′-gagacaggccctaccaccag-3′, IL-1RA R_5′-cgggatga
tcagcctctagtgt-3′ [63], GFAP F_5′-agtggtatcggtccaagtttgc-3′, GFAP R_5′-tggcggcgatagtcattagc-3′ [64],
Tbp F_5′-tgggattgtaccacagctcca-3′, Tbp R_5′-ctcatgatgactgcagcaaacc-3′ [65].
Real-time PCR was performed using TB Green premix Ex Taq II (Takara Bio Inc., Kusatsu, Shiga
Prefecture, Japan) in a DNA thermal cycler (ABI 7300, Applied Biosystems, Foster City, CA, USA),
according to the following protocol: denaturation step- 95 ◦C for 30 s; 40 cycles of 95 ◦C for 15 s,
annealing for 20 s, and annealing temperature at 60 ◦C for 30 s. Dissociation curve analysis was
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performed to confirm the specificity of the final product. Gene expression quantification was based on
the CT values. The expression levels were normalized to an endogenous control, Tbp expression, and
the ratios were multiplied by 100.
4.6. Immunohistochemistry
Six to 8 microns-thick frozen sections of trigeminal ganglion were fixed in 4% paraformaldehyde,
permeabilized with 0.1% Triton and subsequently blocked with Blocking One Histo (Nacalai Tesque,
Kyoto, Japan). Sections were incubated with primary antibodies, rabbit anti-glutamine synthetase
(1:1000; ab49873, Abcam, Cambridge, UK) and goat anti-GFAP (1:500; ab53554, Abcam), overnight at
4 ◦C. Sections were incubated with secondary antibodies for 2 h at room temperature using donkey
anti-goat IgG Alexa Fluor 488 (1:200; ab150129, Abcam) and donkey anti-rabbit Alexa Fluor 555 (1:200;
ab 150074, Abcam). For nuclear staining, 4’, 6-Diamidino-2-phenylindole dihydrochloride (DAPI, 1:100,
Nacalai Tesque, Inc., Kyoto, Japan) was used for 15 min at room temperature, followed by mounting
with Aqua-Poly/Mount (Polysciences, Inc., Warrington, PA, USA). Isotypes (goat IgG bs-0294P, and
rabbit IgG bs-0295P, Bioss Antibodies, Boston, MA, USA) and only secondary antibodies were used
as positive and negative control. Images were observed and acquired by confocal laser-scanning
microscope (LSM 700, Carl Zeiss, Oberkochen, Germany).
4.7. Cytokine Measurement
The TGs were dissociated as described previously [66]. Briefly, the tissues were enzymatically
digested using 0.125% collagenase P (Roche, Indianapolis, IN, USA), 0.02% DNase (Sigma-Aldrich,
St. Louis, MO, USA) and 0.25% trypsin (Sigma, Kanagawa, Japan), and then mechanically triturated
with fire-polished Pasteur pipettes in dissociation solution (5 mL Hank Balanced Salt Solution
(Nacalai Tesque, Inc., Kyoto, Japan) containing 0.295% MgSO4 and 0.02% DNase). Dissociated cells
were plated on uncoated 24-well plates in feeding medium containing minimum essential medium
(MEM) (Life Technologies, Tokyo, Japan), fetal bovine serum (Sigma-Aldrich, St. Louis, MO, USA),
glucose, transferrin, glutamine, and insulin (Sigma-Aldrich, St. Louis, MO, USA). The primary mixed
neuron-glial cell culture was maintained for 5 days. The glial rich culture was prepared from the mixed
culture at day 5, by detaching the cells by 5-min treatment with acutase (Nacalai Tesque, Inc., Kyoto,
Japan) at 37 ◦C and re-plating on an uncoated 24-well plate for 48 h (Figure 10) [28].
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Figure 10. Glial-rich culture, SGCs are identified based on: (a) morphology using light microscopy, 
(b) and immunoreactivity as glutamine synthetase (marker of SGC) and DAPI-positive cells using 
confocal microscopy. Arrow points to the SGCs. Scale bar: 20 μm. 
4.8. Statistical Analysis 
SPSS 25 (IBM, New York, NY, USA) was used to perform statistical analysis. All the results were 
expressed as mean ± standard error of mean (SEM). Within-group differences were examined using 
the “paired t-test”. mRNA expression was compared using one-way analysis of variance (ANOVA), 
followed by Dunnett’s post hoc test. The “t test” was used to examine between-group differences. A 
level of p < 0.05 was considered statistically significant. 
5. Conclusions 
In conclusion, we found that IG CGRP injection induces increased sensitivity to heat. This effect 
was accompanied by an increased SGC and neuronal activation. An increased expression of cytokine 
during the same time within the TG affirm their contribution in the genesis of pain. Additionally, 
injecting the glial inhibitor Minocycline 1 hour before CGRP decreased the CGRP induced thermal 
hyperalgesia, SGC activation and reduced the expression of pro-inflammatory cytokines IL-1β and 
IL-6 in the TG. Taken together, these findings support the notion that increased glial activity 
contributes to hyperalgesia and that glial inhibition can be considered for its management. 
Author Contributions: Conceptualization, Y.M.; methodology, R.A., M.O., S.A., and O.B.; validation, Y.M., R.A. 
and M.O.; formal analysis, Y.O. and M.H.; investigation, S.A., R.A. and T.I.; resources, M.I.; data curation, Y.M. 
and S.A.; writing—original draft preparation, Y.M. and S.A.; writing—review and editing Y.M. Y.O., R.A. and 
O.B.; visualization, Y.M.; supervision, Y.M. and R.A.; project administration, Y.M..; funding acquisition, Y.M. 
Funding: This work was supported by the Ministry of Education Culture, Sports, Science and Technology of 
Japan (No. 26293412, 18H02992). 
Acknowledgments: We are thankful to Naozumi Ishimaru (Professor, Department of Oral Molecular Pathology, 
Graduate School of Biomedical Sciences, Tokushima University, Tokushima) in giving his continuous support 
to conduct this research by using his laboratory instruments and by giving us useful suggestions in writing the 
manuscript. 
Conflicts of Interest: The authors declare no conflict of interest. 
Abbreviations 
CGRP Calcitonin gene-related peptide  
DAPI 4’,6-Diamidino-2-phenylindole dihydrochloride  
GFAP Anti-glial fibrillary acidic protein  
Figure 10. Glial-rich culture, SGCs are identified based on: (a) morphology using light microscopy,
(b) and immunoreactivity as glutamine synthetase (marker of SGC) and DAPI-positive cells using
confocal microscopy. Arrow points to the SGCs. Scale bar: 20 µm.
The cytokine released in culture media from purified SGC cultures was evaluated under control
conditions (i.e., samples exposed to MEM alone) and following overnight exposure (12 h) to 1 µM
CGRP [28]. Cytokine measurement of conditioned medium derived from glial rich culture exposed to
CGRP and control conditions was performed using the Proteome profiler Rat Cytokine Array Panel A
(R&D System, Minneapolis, MN, USA) according to the manufacturer’s instructions. This array kit
allows to simultaneously detect 29 different rat cytokines and chemokines. Spot densitometry was
performed using Chemi Doc systems (BioRad, Hercules, CA, USA). Background staining and spot size
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were analyzed and the results were expressed as the fold change of CGRP-treated cultures in relation
to control conditions.
4.8. Statistical Analysis
SPSS 25 (IBM, New York, NY, USA) was used to perform statistical analysis. All the results were
expressed as mean ± standard error of mean (SEM). Within-group differences were examined using
the “paired t-test”. mRNA expression was compared using one-way analysis of variance (ANOVA),
followed by Dunnett’s post hoc test. The “t test” was used to examine between-group differences.
A level of p < 0.05 was considered statistically significant.
5. Conclusions
In conclusion, we found that IG CGRP injection induces increased sensitivity to heat. This effect
was accompanied by an increased SGC and neuronal activation. An increased expression of cytokine
during the same time within the TG affirm their contribution in the genesis of pain. Additionally,
injecting the glial inhibitor Minocycline 1 h before CGRP decreased the CGRP induced thermal
hyperalgesia, SGC activation and reduced the expression of pro-inflammatory cytokines IL-1β and
IL-6 in the TG. Taken together, these findings support the notion that increased glial activity contributes
to hyperalgesia and that glial inhibition can be considered for its management.
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